文献速递肝病消化道肿瘤与早癌

靶向NEK9通过重塑免疫抑制微环境与免疫治疗在肝细胞癌中协同增效

Targeting NEK9 synergises with immunotherapy in hepatocellular carcinoma by remodelling the immunosuppressive microenvironment.
PubMed 文献 · Gut · 2026-06-25

该研究探讨NEK9作为肝细胞癌免疫逃逸驱动因子及治疗靶点的作用。NEK9在HCC中显著上调,与生存不良、CD8+ T细胞浸润减少及MDSCs增加相关。药理抑制NEK9可逆转免疫抑制微环境,两种新型小分子抑制剂MIPO和FPTP与抗PD-L1治疗强协同,增强CD8+ T细胞效应功能并抑制肿瘤生长。

要点

  • NEK9在HCC中上调,与预后不良和免疫抑制微环境相关。
  • NEK9通过磷酸化TRIM28和USP46稳定NF-κB2,驱动PD-L1和CXCL1转录。
  • NEK9抑制剂MIPO和FPTP与抗PD-L1协同,增强抗肿瘤免疫。

核心结论

  • NEK9是肝细胞癌免疫逃逸的可成药驱动因子,靶向NEK9可重塑免疫抑制微环境并与PD-L1阻断协同。

研究设计与样本

  • 研究分析HCC队列中NEK9表达及临床相关性,并在HCC细胞系和原位小鼠模型中采用遗传和特异性药理方法进行功能研究。
  • 利用单细胞RNA测序、流式细胞术和多重组免疫组化全面分析肿瘤微环境。
  • 通过免疫共沉淀、磷酸化蛋白质组分析和激酶实验获取机制见解。
  • 使用零交互效力(ZIP)参考模型定量评估NEK9抑制与PD-L1阻断的协同作用。

主要发现

  • NEK9在HCC中显著上调,与生存不良、瘤内CD8+ T细胞浸润减少和髓源性抑制细胞(MDSCs)增加相关。
  • NEK9直接磷酸化TRIM28和USP46,稳定核因子-κB2(NF-κB2),驱动PD-L1和CXCL1转录,促进CD8+ T细胞功能障碍和CXCR2依赖的MDSCs募集。
  • 药理抑制NEK9使NF-κB2不稳定并逆转免疫抑制肿瘤微环境。
  • 发现两种新型小分子NEK9抑制剂MIPO和FPTP,与抗PD-L1治疗强协同,增强CD8+ T细胞效应功能和体内肿瘤抑制。

临床怎么用

  • 靶向NEK9可能作为克服肝细胞癌免疫检查点抑制剂耐药的策略,与PD-L1阻断联合使用。
  • MIPO和FPTP是候选NEK9抑制剂,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs) demonstrate limited efficacy in hepatocellular carcinoma (HCC), largely attributable to a profoundly immunosuppressive tumour microenvironment (TME). OBJECTIVE: To investigate the kinase never-in-mitosis A-related kinase 9 (NEK9) as a potential tumour-intrinsic driver of immune evasion and therapeutic target. DESIGN: NEK9 expression and its clinical relevance were analysed in HCC cohorts. Functional investigations employed genetic and specific pharmacological approaches in HCC cell lines and orthotopic mouse models. The TME was comprehensively profiled using single-cell RNA sequencing, flow cytometry and multiplex immunohistochemistry. Mechanistic insights were gained through co-immunoprecipitation, phosphoproteomic analysis and kinase assays. Synergy between NEK9 inhibition and programmed death-ligand 1 (PD-L1) blockade was quantitatively assessed using zero interaction potency (ZIP) reference models. RESULTS: NEK9 was significantly upregulated in HCC and correlated with poor survival, diminished intratumoral CD8+ T cell infiltration and increased myeloid-derived suppressor cells (MDSCs). Mechanistically, NEK9 directly phosphorylated TRIM28 and USP46, stabilising nuclear factor-κB2 (NF-κB2) and driving PD-L1 and CXCL1 transcription, thereby promoting CD8+ T cell dysfunction and CXCR2-dependent recruitment of MDSCs. Pharmacological NEK9 inhibition destabilised NF-κB2 and reversed the immunosuppressive TME. Importantly, two novel small-molecule NEK9 inhibitors (MIPO, FPTP) were identified, which synergised strongly with anti-PD-L1 therapy, enhancing CD8+ T cell effector function and tumour suppression in vivo. CONCLUSIONS: NEK9 is a druggable driver of immune evasion in HCC. Targeting NEK9 remodels the immunosuppressive TME and synergises with PD-L1 blockade, offering a promising strategy to overcome ICI resistance.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Lu G, Du R, Wan Y, et al. Targeting NEK9 synergises with immunotherapy in hepatocellular carcinoma by remodelling the immunosuppressive microenvironment. Gut. 2026. PMID: 42350096. doi:10.1136/gutjnl-2026-338449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。